or Try an Advanced Search...

    Adverum Biotechnologies Stocks List

    Symbol Grade Name % Change
    ADVM D Adverum Biotechnologies, Inc. 1.58
    CLSD F Clearside Biomedical, Inc. -0.98
    View As Page of Charts
    Related Industries: Biotechnology
    Related Stock Lists: Macular Degeneration Retina Wet Age Related Macular Degeneration Biopharmaceutical Disease Drug Therapies Eye Gene Therapy Gene Therapy Of The Human Retina Gene Therapy Products Genetic Diseases Macular Edema Medicine Non Infectious Uveitis Ophthalmology Rare Genetic Disease Regeneron Retinal Vein Occlusion Uveitis Veins

    Related ETFs - A few ETFs which own one or more of the above listed Adverum Biotechnologies stocks.

    Symbol Grade Name Weight
    LABD D Direxion Daily S&P Biotech Bear 3X Shares 0.55
    EVNT B AltShares Event-Driven ETF 0.33
    IWC B iShares Microcap ETF 0.06
    IWM B iShares Russell 2000 ETF 0.01
    IWN C iShares Russell 2000 Value ETF 0.01
    View all Adverum Biotechnologies ETFs...
    Compare ETFs
    Compare EVNT to IWM Compare LABD to IWC Compare LABD to IWN

        Adverum Biotechnologies Stocks Recent News

        Date Stock Title
        Oct 31 CLSD Clearside Biomedical to Report Third Quarter 2024 Financial Results and Provide Corporate Update on Tuesday, November 12, 2024
        Related Industries: Biotechnology
        Related Stock Lists: Macular Degeneration Retina Wet Age Related Macular Degeneration Biopharmaceutical Disease Drug Therapies Eye Gene Therapy Gene Therapy Of The Human Retina Gene Therapy Products Genetic Diseases Macular Edema Medicine Non Infectious Uveitis Ophthalmology Rare Genetic Disease Regeneron Retinal Vein Occlusion Uveitis Veins
        Adverum Biotechnologies

        Avalanche Biotechnologies is a publicly traded (NASDAQ:AAVL) biotechnology company in the NASDAQ Biotechnology Index that is focused on diseases of the eye. This includes macular degeneration, retinal vein occlusion, diabetic macular edema, and others. The company's only drug in clinical trials, AVA-101, designed to treat macular degeneration, had poor results after initial clinical trials in 2015. In 2016 Avalanche Biotechnologies merged with Annapurna Therapeutics to form Advertum Biotechnologies, Inc.

        More about Adverum Biotechnologies
        Browse All Tags